{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:42:38Z","timestamp":1792816958307,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier","isbn-type":[{"value":"9780443429934","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.acc.2025.01.001","type":"book-chapter","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:21:10Z","timestamp":1742430070000},"page":"121-154","source":"Crossref","is-referenced-by-count":3,"title":["Lupus nephritis II: Treatment and monitoring"],"prefix":"10.1016","author":[{"given":"Chrisanna","family":"Dobrowolski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Min","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Kharouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Parnizari","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Wither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Whitall","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arenn","family":"Jauhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000932","article-title":"Remission of lupus nephritis: the trajectory of histological response in successfully treated patients","volume":"10","author":"Malvar","year":"2023","journal-title":"Lupus Sci. Med."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2025.01.001_bib8","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","author":"Kidney Diseaes: Improving Global Outcomes Glomerular Diseases Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum Dis."},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","article-title":"Prognostic factors in lupus nephritis. Contribution of renal histologic data","volume":"75","author":"Austin","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2025.01.001_bib11","series-title":"Heidelberg","first-page":"89","article-title":"Lupus nephritis. fundamentals of renal pathology","author":"Fogo","year":"2014"},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5858\/133.2.233","article-title":"Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications","volume":"133","author":"Seshan","year":"2009","journal-title":"Arch. Pathol. Lab. Med"},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.ackd.2019.08.011","article-title":"Lupus podocytopathy: an overview","volume":"26","author":"Oliva-Damaso","year":"2019","journal-title":"Adv. Chronic. Kidney Dis."},{"issue":"9","key":"10.1016\/bs.acc.2025.01.001_bib16","article-title":"Lupus nephritis with collapsing glomerulopathy: a rare association","volume":"15","author":"Dubey","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.11751111","article-title":"Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease","volume":"7","author":"Salvatore","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2215\/CJN.03590412","article-title":"Collapsing glomerulopathy in systemic lupus erythematosus: an extreme form of lupus podocytopathy?","volume":"7","author":"Haas","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/bs.acc.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203317692419","article-title":"Prognostic significance of renal vascular pathology in lupus nephritis","volume":"26","author":"Mejia-Vilet","year":"2017","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/0886022X.2019.1702057","article-title":"Renal microvascular lesions in lupus nephritis","volume":"42","author":"Ding","year":"2020","journal-title":"Ren. Fail"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/bs.acc.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2025.01.001_bib25","article-title":"EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis - the European renal association (ERA) - immunonephrology working group (ERA-IWG) perspective","author":"Frangou","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/bs.acc.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/bs.acc.2025.01.001_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214832","article-title":"Old and new calcineurin inhibitors in lupus nephritis","volume":"10","author":"Ponticelli","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/bs.acc.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"20","key":"10.1016\/bs.acc.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/bs.acc.2025.01.001_bib32","first-page":"543","article-title":"Determining treatment response in lupus nephritis","volume":"18","author":"Allison","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"10.1016\/bs.acc.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/acr.23792","article-title":"Azathioprine and mycophenolate mofetil adherence patterns and predictors among medicaid beneficiaries with systemic lupus erythematosus","volume":"71","author":"Feldman","year":"2019","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/bs.acc.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/IJNRD.S335371","article-title":"Mechanism of action and efficacy of immunosupressors in lupus nephritis","volume":"14","author":"Alamilla-Sanchez","year":"2021","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"issue":"11","key":"10.1016\/bs.acc.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.02670409","article-title":"Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option","volume":"4","author":"McKinley","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/bs.acc.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"8345737","DOI":"10.1155\/2022\/8345737","article-title":"Revisited cyclophosphamide in the treatment of lupus nephritis","volume":"2022","author":"Quan","year":"2022","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41523-021-00340-7","article-title":"GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy","volume":"7","author":"Li","year":"2021","journal-title":"NPJ. Breast Cancer"},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","article-title":"Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann. Intern. Med"},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/0019-5154.190107","article-title":"Belimumab in systemic lupus erythematosus","volume":"61","author":"Srivastava","year":"2016","journal-title":"Indian J. Dermatol."},{"issue":"10289","key":"10.1016\/bs.acc.2025.01.001_bib45","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.191008","article-title":"Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST)","volume":"48","author":"Takeuchi","year":"2021","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.130005","article-title":"Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment","volume":"41","author":"Touma","year":"2014","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrrheum.2009.235","article-title":"Therapy: hydroxychloroquine in SLE: old drug, new perspectives","volume":"6","author":"Dorner","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","article-title":"Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival","volume":"17","author":"Siso","year":"2008","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/acr.25228","article-title":"Reference range of hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares","volume":"76","author":"Garg","year":"2024","journal-title":"Arthritis Care. Res. (Hoboken)"},{"issue":"4S","key":"10.1016\/bs.acc.2025.01.001_bib53","first-page":"S1","article-title":"Improving global outcomes glomerular diseases work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis. Care Res. (Hoboken)"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatol (Oxf)"},{"issue":"9","key":"10.1016\/bs.acc.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European league against rheumatism\/american college of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/bs.acc.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2009.117200","article-title":"European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies","volume":"69","author":"Mosca","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/bs.acc.2025.01.001_bib58","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"8822","key":"10.1016\/bs.acc.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/bs.acc.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann. Intern. Med."},{"issue":"16","key":"10.1016\/bs.acc.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group","volume":"343","author":"Chan","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci. Med."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib67","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2025.01.001_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci. Med."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/bs.acc.2025.01.001_bib70","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"issue":"10","key":"10.1016\/bs.acc.2025.01.001_bib72","article-title":"A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study [abstract]","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib73","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/annrheumdis-2023-eular.1727","article-title":"OP0137\u2005Efficacy and safety of telitacicept, a novel blys\/april dual inhibitor, in patients with systemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week Study","volume":"82","author":"Wang","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"issue":"5","key":"10.1016\/bs.acc.2025.01.001_bib74","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev."},{"issue":"6","key":"10.1016\/bs.acc.2025.01.001_bib75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/0961203318758506","article-title":"Systemic lupus erythematosus (SLE) responder index response is associated with global benefit for patients with SLE","volume":"27","author":"Furie","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","article-title":"JAK3-STAT pathway blocking benefits in experimental lupus nephritis","volume":"18","author":"Ripoll","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"10143","key":"10.1016\/bs.acc.2025.01.001_bib77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/bs.acc.2025.01.001_bib78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/bs.acc.2025.01.001_bib79","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/bs.acc.2025.01.001_bib80","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2025.01.001_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.acc.2025.01.001_bib82","article-title":"CAR T cell therapy leads to long-term abrogation of autoimmunity in SLE patients while vaccination responses are maintained [abstract]","volume":"75","author":"Schett","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/bs.acc.2025.01.001_bib83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1191\/0961203305lu2249oa","article-title":"Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria","volume":"14","author":"Tse","year":"2005","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/bs.acc.2025.01.001_bib84","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatol (Oxf)"},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1191\/0961203305lu2076oa","article-title":"Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy","volume":"14","author":"Kanda","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/bs.acc.2025.01.001_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.001_bib87","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of cardiac and renal outcomes in systemic lupus erythematosus [abstract]","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/bs.acc.2025.01.001_bib88","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2025.01.001_bib89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2478\/rir-2023-0018","article-title":"Lupus clinical trials and the promise of future therapies","volume":"4","author":"Khalili","year":"2023","journal-title":"Rheumatol Immunol. Res."},{"issue":"1","key":"10.1016\/bs.acc.2025.01.001_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000360","article-title":"Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers","volume":"7","author":"Arriens","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/bs.acc.2025.01.001_bib91","series-title":"Lahita's Systemic Lupus Erythematosus","first-page":"673","article-title":"Chapter 41 - challenges of systemic lupus clinical trials","author":"Merrill","year":"2021"},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib92","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1573397117666210301144651","article-title":"Medication adherence of patients with systemic lupus erythematosus and rheumatoid arthritis considering the psychosocial factors, health literacy and current life concerns of patients","volume":"17","author":"Shenavandeh","year":"2021","journal-title":"Curr. Rheumatol. Rev."},{"issue":"4","key":"10.1016\/bs.acc.2025.01.001_bib93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bcp.14240","article-title":"How the EMERGE guideline on medication adherence can improve the quality of clinical trials","volume":"86","author":"Eliasson","year":"2020","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242325000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242325000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:26:06Z","timestamp":1743744366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242325000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443429934"],"references-count":93,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2025.01.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}